Aquaporin initiates rights issue

Aquaporin A/S has launched a rights issue of up to 77,536,770 new shares at DKK 1 each to raise gross proceeds of up to DKK 78 million (subscription ratio 10:3, subscription period Jan 7–20, 2026). The raise is intended to fund operations into Q2 2027 and development/commercialization of its second‑generation Aquaporin Inside (AiG2) technology, but the company warns additional capital will likely be required before Q2 2027 and that insufficient proceeds would create material going‑concern risk. Major shareholders and management have provided pre‑subscription and guarantee commitments totaling up to DKK 21.6 million (c.27.9% of the offering), subject to conditions including a DKK 50 million proceeds threshold; existing shareholders face up to ~77% dilution if they do not participate.

Analysis

Market structure: The rights issue (DKK78m max; DKK1/share) imposes up to ~77% dilution for current holders and shifts economic power toward new/guaranteeing shareholders (M. Goldschmidt, VP Capital). Direct beneficiaries are suppliers and incumbents in industrial water treatment (Xylem, Pentair, Veolia) who face less threat from a cash-strapped challenger; direct losers are passive Aquaporin holders facing immediate equity value dilution and potential forced recapitalizations.

Risk assessment: Key tail risk is a failed raise below DKK50m (threshold for many guarantees) triggering near-term going‑concern issues and an accelerated dilutive recapitalization or asset sale; probability concentrates around the subscription result published Jan 22, 2026. Short-term horizon (days–weeks) centers on rights trading (Jan 5–16) and subscription window (Jan 7–20); medium term (months) depends on whether additional funding is secured before Q2 2027; long-term upside hinges on AiG2 commercialization in 2027–28 but is binary and capital‑intensive.

Trade implications: Tactical opportunities include short-biased exposure to Aquaporin around the rights period and selective long exposure to larger, cash‑generative water-tech names (XYL, PNR, VIE) that gain share if Aquaporin weakens. Volatility around rights creates options plays (protective puts or put spreads) and a small arbitrage in traded Pre-emptive Rights if they price an implied raise <DKK50m.

Contrarian angles: The market may underweight Aquaporin’s IP value and AiG2 optionality — if the company clears ≥DKK50m and secures predictable milestones, equity can re-rate; conversely, guarantees conditioned on thresholds could collapse quickly, producing a non-linear downside. Watch-blocking stakes by guarantors could also set up a strategic buyout if share price compresses materially.

Key Decisions for Investors

• Establish a tactical short in Aquaporin shares equal to 1% of NAV during Jan 5–20, 2026; increase to 3% NAV if the announced gross proceeds on Jan 22 are <DKK50m; cover 2–4 weeks after new shares list (target exit by Feb 28, 2026) or if share moves against position by 15%.
• Deploy 2–3% NAV long into large water-tech incumbents as a sector hedge: 60% Xylem (XYL), 40% Pentair (PNR). Build positions on any Aquaporin-triggered sell-off >20% and hold 6–12 months; take profits at +25% or if macro risk rises.
• If Pre-emptive Rights trade <DKK0.08 during Jan 5–16, 2026, allocate up to 0.5% NAV to buy rights (arbitrage): exercise only if implied market pricing indicates the raise will be ≥DKK50m; limit loss to full premium paid and exit immediately after Jan 22 result.
• Do NOT participate in subscribing new Aquaporin shares at DKK1 unless company confirms gross proceeds ≥DKK50m and publishes a committed 12‑month cash runway; only consider a long re-entry after demonstrable commercial milestones on AiG2 (revenue or binding offtake) in 2027.